title: The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate the effectiveness of 1 step titrate up regimen.
  
  
  METHODS
  Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated at week 8.
  
  
  RESULTS
  A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject's LDL-C levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n = 25) required the sole titration. Each dose provided significant decreases in LDL-C (average -46.4%). Only 36 subjects experienced treatment related adverse events, the majority of these were in the high-risk group (n = 22) with only one subject registering a serious adverse event.
  
  
  CONCLUSIONS
  Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting dose has contributed in the achievement of cholesterol reduction.
authors.affiliation: Division of Endocrinology, Department of Medicine, Rajavithi Hospital, 2 Rajavithi Rd, Bangkok, Thailand.
authors.forename: Chaicharn
authors.initials: C
authors.lastname: Deerochanawong
authors.forename: Peera
authors.initials: P
authors.lastname: Buranakitjaroen
authors.forename: Wannee
authors.initials: W
authors.lastname: Nitiyanant
authors.forename: Jithanorm
authors.initials: J
authors.lastname: Suwantamee
authors.forename: Chumpol
authors.initials: C
authors.lastname: Piamsomboon
authors.forename: Varaphon
authors.initials: V
authors.lastname: Vongthavaravat
authors.forename: Nijasri Charnnarong
authors.initials: NC
authors.lastname: Suwanwela
authors.forename: Natapong
authors.initials: N
authors.lastname: Kosachunhanun
authors.forename: Apichard
authors.initials: A
authors.lastname: Sukonthasarn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin